Pathophysiological assessment by FAPI-PET targeting cancer-associated fibroblasts in proton therapy

Pathophysiological assessment by FAPI-PET targeting cancer-associated fibroblasts in proton therapy - Pathophysiological assessment by FAPI-PET in proton therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000052534

Enrollment

Registered

2023-10-18

Start date

2023-10-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

PET examination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients scheduled to receive proton therapy for malignant tumors of the lung, hepatobiliary pancreas, digestive organs, and bone and soft tissue (2) Patients who have the ability to understand and comply with the contents of this study (3) Patients who can obtain written consent from the subjects themselves.

Exclusion criteria

Exclusion criteria: (1) Pregnant women, lactating women, and women who may be pregnant (2) Pediatric patients who require sedation (3) Patients whom the principal investigator or co-investigators deem inappropriate to conduct this study.

Design outcomes

Primary

Measure	Time frame
Qualitative and quantitative evaluation of FAPI-PET images	—

Secondary

Measure	Time frame
Qualitative evaluation of CT and 18F-FDG PET images and comparison with quantitative evaluation indices	—

Countries

Japan

Contacts

Public ContactToshimitsu Momose

Southern Tohoku Research Institute for Neuroscience Drug Discovery and Cyclotron Research Center

tmomo-tky@umin.ac.jp024-934-5610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026